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Clinical review
Clostridium difficile associated diarrhoea: diagnosis and
treatment
John Starr
While John Starr was working as a senior registrar at the Hammersmith Hospital in London, an
upsurge in episodes of Clostridium difficile associated diarrhoea seemed to be associated with
increasing use of third generation cephalosporins. This article seeks to clarify some of the diagnostic
problems and help with appropriate treatment of this condition.
Clostridium difficile associated diarrhoea is a serious
condition with a mortality of up to 25% in frail elderly
people.1 It affects older, frailer, hospitalised patients and
also younger patients who are immunosuppressed.
Cross infection by C difficile is common in neonatal
units, but neonates do not seem to develop C difficile
associated diarrhoea.
The diagnosis of C difficile associated diarrhoea
depends on:
x Presence of diarrhoea, defined as an increase in
stool liquidity usually accompanied by an increased
frequency of bowel motions. A formal cut-off is the
passing of more than 300 ml of liquid stool in 24 hours
x Detection of toxins produced by C difficile in the
stools.
The patient may also experience abdominal pain
and have systemic features of malaise, fever, dehydra-
tion, and delirium. A pseudomembranous colitis is
present in severe cases. In this state there is sloughing
of the colonic epithelium, which is severely inflamed
due to the cytotoxic action of C difficile.
C difficile associated diarrhoea is classically associ-
ated with clindamycin, but it may occur after exposure
to a wide range of antibiotics.
Symptoms usually start during antibiotic treatment
or shortly afterwards. Symptoms can be delayed by a
few weeks, so it is worth asking patients whether they
are currently taking, or have recently taken, antibiotics.
How does it happen?
C difficile is spread by the faecal-oral route, albeit indi-
rectly through spores left on surfaces. C difficile is an
anaerobic, Gram positive, spore forming bacterium
that is the major identifiable cause of antibiotic associ-
ated diarrhoea.
x The prevalence of asymptomatic colonisation in the
community is less than 5%2–4
x The prevalence of asymptomatic colonisation in
hospital, especially in older people, is higher at over
20%.5–7
In a proportion of those colonised, perhaps around
one third,7 C difficile produces toxins that cause
diarrhoea. The two principal toxins, A and B, share
63% of amino acid sequence homology and act on
small GTP-binding proteins (these are part of the large
family of guanine nucleotide binding proteins that are
coupled to many membrane receptors and are
implicated in many diseases).
Toxin B is around 1000 times more cytotoxic than
toxin A.8 Toxin A is also an enterotoxin in that it loos-
ens the tight junctions between the epithelial cells that
line the colon, which helps toxin B enter into epithelial
cells.
Some strains also produce a binary toxin, but its
role in human disease is uncertain.9
C difficile associated diarrhoea is therefore charac-
terised by a progression from an uncolonised state,
through to C difficile colonisation, followed by toxin
production. In part this depends on the specific strain
of C difficile, with one strain (toxigenic S-type 5236)
responsible for around 70% of cases in the UK.6 How-
ever, host factors that predispose to colonisation and
toxin production are equally important.
One systematic review identified several risk factors
for C difficile associated diarrhoea10:
x Increasing age (excluding infancy)
x Severe underlying disease
x Non-surgical gastrointestinal procedures
x Presence of a nasogastric tube
x Receiving anti-ulcer medications
x Stay on intensive care unit
x Long duration of hospital stay
x Long duration of antibiotic course
x Receiving multiple antibiotics.
Another systematic review identified clindamycin,
cephalosporins, and penicillins as the classes of anti-
biotics most associated with C difficile associated
diarrhoea.11
One study found that the risk factors for colonisa-
tion in a medicine of the elderly hospital (age, admission
from another hospital, use of non-cephalosporin and
cephalosporin antibiotics) were different from the risk
factors for the transition between culture-positive and
toxin-positive status (antibiotic use only).12
A failure to mount an immune response is
associated with colonisation and toxin production.13 14
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In addition, the case mix on wards, and bays within
wards, is important because of a potential herd
immunity effect that can prevent epidemic outbreaks of
C difficile associated diarrhoea.15 For example, if only a
few patients on a ward have been exposed to antibiotics,
most of those who have not been treated with antibiotics
will retain their normal colonic bacterial flora and will
not develop C difficile associated diarrhoea.
For an outbreak to occur, each case of C difficile
associated diarrhoea must give rise to more than one
new case. This depends not only on the infectivity of
the agent, in this case C difficile, but also on the propor-
tion of surrounding patients who are susceptible to
infection. So as the proportion of patients on the ward
who have received antibiotics and who are old rises, a
threshold is reached where the product of the infectiv-
ity of C difficile and the proportion of susceptible
patients is greater than one, and an outbreak of C diffi-
cile associated diarrhoea occurs.
Infectivity depends not just on the characteristics
of the specific strain, but on factors that impact on
cross infection (hygiene, bed spacing, and shared toilet
facilities).
How should I treat it?
Treatment can be divided into:
x Therapy for patients with C difficile associated
diarrhoea
x Measures to prevent other patients developing it.
Patients with C difficile associated diarrhoea
Therapy for patients with C difficile associated
diarrhoea comprises:
x Supportive measures (adequate fluid and electrolyte
replacement)
x Withdrawal of current antibiotic therapy if possible
x Antibiotic treatment to eradicate C difficile.
Standard first line antibiotic therapy is metronida-
zole 400 mg administered orally three times a day. An
alternative is oral vancomycin 125 mg four times a day,
or at a higher dose for severe episodes. One study sug-
gested this should be used as first line treatment for
patients with albumin < 25 g/l or for patients who are
in intensive care.16 Resistance to metronidazole and
vancomycin is not reported, but changing antibiotic is
often tried empirically after one week if symptoms
have not resolved.
Placebo arms in clinical trials suggest that C difficile
associated diarrhoea will resolve without antibiotic
therapy in around 20% of patients. An earlier
systematic review found that metronidazole and
vancomycin produced comparable results.17
If a patient can’t take oral medications, a nasogastric
tube will be needed to administer antibiotics because an
enteral route is required to treat the infection.
Evidence is inadequate to support the use of pre-
biotics (nutrients that encourage “normal” colonic
bacterial flora) or probiotics (livemicrobial supplements,
for example containing bifidobacteria, lactobacilli, and
so on) for treating patients with established C difficile
associated diarrhoea.18
Preventing C difficile associated diarrhoea
Prevention of C difficile associated diarrhoea consists of
general infection control measures and those more
specific for C difficile.
Diagnosis now tends to be made by detecting toxin,
and so laboratories no longer culture C difficile. This
hampers wider public health control of outbreaks and
monitoring of antibiotic sensitivities because there may
be a delay in detecting emerging epidemic strains.19 It
also impairs diagnostic evaluation because cytotoxin is
absent from the stools of a small proportion of
endoscopically proved cases.20
Each unit should evaluate its case mix and,
therefore, its risk of an outbreak of C difficile associated
diarrhoea. For those at high risk, strict control of anti-
biotic prescribing may be useful.21
One study showed that several measures signifi-
cantly reduced the incidence of C difficile associated
diarrhoea22:
x Revision and enforcement of the isolation policy to
include wearing of gloves and gowns, and hand wash-
ing by healthcare staff; patients isolated in single or
double bedded rooms or cohort bays; equipment such
as thermometers and stethoscopes dedicated to each
patient
x Monthly educational programme for all healthcare
workers
x Phenolic disinfectant used for environmental clean-
ing
x Triclosan (0.03%) soap used for hand washing
x Sterilisation department centralised
x Cart washer installed for cleaning wheelchairs and
stretchers that have not come into direct contact with
patients
x Aggressive surveillance activity.
Evidence is poor for routine hand cleansing and
evidence is weak for environmental disinfectant
cleansing.23 24 Nevertheless, such interventions are
likely to be as important as antibiotic control.25
Probiotics are probably effective in preventing
recurrence of C difficile associated diarrhoea,26 but the
evidence for primary prevention, even in targeted
populations, is equivocal.18 27
Recurrence
Recurrence can occur in up to one third of cases. It is
sometimes difficult to determine whether this is due to
failure of eradication of C difficile and subsequent
recolonisation with normal colonic bacterial flora, or to
a new infection of a susceptible patient. Strain typing
may help, but its use is limited because the “epidemic”
strain accounts for around 70% of infections, and colo-
nisation with more than one strain is not uncommon.
It is not unusual for an initial episode of C difficile
associated diarrhoea to affect the patient’s nutritional
Clinical tips
You should treat patients whose stools contain a
positive culture but do not contain toxins only if you
strongly suspect that they have C difficile associated
diarrhoea and if they are systemically unwell. This is
because C difficile may be found incidentally in the
stools of patients whose diarrhoea is due to other
causes.
Use high dose vancomycin as first line treatment for
patients on the intensive care unit or for patients with
low albumin levels.
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status and for the serum albumin to remain low at the
time of recurrence. This is an indication to use high
dose vancomycin.
Vaccines
A report to the Department of Health in 2004 on
appropriate public health surveillance of C difficile
reviewed current research.28 Key themes were infection
control, antibiotic restriction policies (especially of
third generation cephalosporins), and use of probiot-
ics. It also noted that vaccines against C difficile toxins
have been successful in animal models and that early
safety trials in humans have been satisfactory. However,
active immunisation may not be effective in people
most at risk of C difficile, who characteristically fail to
mount an immune response to C difficile infection.
Moreover, local colonic immunoglobulin A (IgA)
production may be more important in protecting
against C difficile associated diarrhoea than humoral
IgG, and colonic IgA production is impaired in patients with C difficile associated diarrhoea.
29 In view
of this, passive immunisation, for example with pooled
human immunoglobulin, may be a more promising
strategy.30
In the meantime, clinicians will need to weigh the
possible advantages of using vancomycin first line,
especially at high dose, against the potential problems
of inducing greater vancomycin resistant enterococci.1
Models and analysis
Looking to the future, one of the major difficulties is
applying randomised controlled trial methodology to
studying a condition that depends on herd immunity
and for which there are many known confounding
variables. These “herds” are spatially and temporally
discrete but, in general, the number of cases of C diffi-
cile associated diarrhoea within a herd is too small for a
randomised controlled trial. Mathematical modelling is
therefore an alternative.
One promising approach is to apply stochastic
models (models that deal with small numbers of
chance events) to observational data.31 Such random
stochastic events can be simulated by Monte Carlo
methods. However, events are linked spatially and tem-
porally and are therefore not individually independent.
Fortunately,mathematical methods such as Markov
chain models can be used. These were developed to
understand paths of cosmic particles as they collide
with atoms on entering the earth’s atmosphere. These
models can help us conduct research on patients with
C difficile associated diarrhoea.
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Sample questions
Here is a small sample of the questions that you can
find at the end of this module. To see all the questions
and to get the answers, go to www.bmjlearning.com/
and search for “clostridium difficile”
1. A 79 year old man in a nursing home has mild
diarrhoea and his stool samples are positive for
C difficile toxin. He is otherwise well. Which of the
following treatments would you give him?
a. He should be given probiotics
b. He should be treated with metronidazole 400 mg
by mouth three times a day
c. He should be treated with vancomycin 250 mg
four times a day
2. A 70 year old woman on ITU develops severe
diarrhoea, abdominal pain, pyrexia, and delirium.
Stool samples are culture-positive for C difficile, but
toxin is not detected. What should be the first step in
her management?
a. She should be treated with vancomycin 250 mg
four times a day
b. She should be treated with metronidazole 400 mg
three times a day
c. She should be treated expectantly, and antibiotics
started only if her stools become toxin positive
3. A 75 year old man is found to have C difficile in his
stools. But he is asymptomatic and there are no toxins
in his stools. What should you advise?
a. Start metronidazole
b. Start vancomycin
c. Observe him off treatment
4. In what proportion of people who are colonised
with C difficile does the bacterium produce toxins that
cause diarrhoea?
a. 10%
b. 30%
c. 60%
5. You diagnose a 65 year old man with C difficile
associated diarrhoea. You want him to start
metronidazole, but he is unwilling and asks whether
his symptoms could resolve on their own. What
percentage of patients with C difficile associated
diarrhoea will get better without antibiotic therapy?
a. About 20%
b. About 50%
c. About 80%
Summary points
Clostridium difficile associated diarrhoea is the
most common cause of antibiotic associated
diarrhoea in hospital
Oral metronidazole 400 mg three times a day and
vancomycin 125 mg four times a day are the
treatments of choice. You should usually continue
treatment until symptoms stop
Probiotics may be useful for preventing
recurrence
Evidence for the effectiveness of infection control
measures is limited
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Lesson of the week
Paralytic rabies after a two week holiday in India
Tom Solomon, Denise Marston, Macpherson Mallewa, Tim Felton, Steve Shaw,
Lorraine M McElhinney, Kumar Das, Karen Mansfield, Jane Wainwright, Georges Ng Man Kwong,
Anthony R Fooks
Rabies is an acute infection of the central nervous
system (CNS) and caused by rabies virus or related
members of the genus Lyssavirus, family Rhabdoviri-
dae.1 The virus is usually transmitted through a dog bite
and produces one of the most important viral encepha-
litides worldwide, with at least 40 000 deaths reported
annually.2 However, it is rare in the United Kingdom,
where just 12 cases have been reported since 19773: 11
were imported from overseas, and one occurred in a bat
handler infected in Scotland with European bat lyssavi-
rus type 2a.4 Most UK patients presented with furious
rabies, which is characterised by hydrophobia and
spasms. We report a case of paralytic rabies in a tourist
after a two week holiday in Goa, India.
Case report
A woman in her late 30s was admitted to her local gen-
eral hospital under the orthopaedic surgeons, with
lower back pain radiating to the left leg. The pain had
started four days earlier, was severe and shooting in
nature, and was getting worse. She had been seen twice
in casualty in the preceding days, and by the time of
admission she was unable to walk. She also had a head-
ache and had vomited once. Three and a half months
before admission, during a two week holiday to Goa,
India, she had been bitten by a dog; she was walking in
the street when a puppy on a lead nipped her on the
left leg. There was a slight graze, which she wiped with
a tissue, but she did not seek further medical help. Her
family reported that she was not aware of the risk of
rabies and had not received any pre-exposure or post-
exposure vaccination. She had also had intermittent
diarrhoea for the past four months, which preceded
her trip to India, but gastroscopy and flexible
sigmoidoscopy on return from India were normal. On
examination she had a temperature of 38.5°C. The left
leg, which was extremely painful and required
morphine, was areflexic and weak, with sensory loss in
L4-S1 dermatomes. She had leucocytosis. A computed
tomography scan of the spine looking for a prolapsed
disc was normal. Over the next few days she developed
a sore throat and had difficulty swallowing, a swollen
left eyelid, a goose pimple rash on her skin, and
marked bilateral loss of hearing. On day 8 the patient
was referred to the medical team, which noted that she
was now lethargic and had flaccid weakness in both
legs and arms. A provisional diagnosis of Guillain-
Barré syndrome was made, and she was treated with
intravenous immunoglobulin. A lumbar puncture
found clear cerebrospinal fluid with a white cell count
of 11 cells/l (9 lymphocytes, 2 polymorphonuclear
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